NCT00394901

A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia

A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin In The Treatment Of Postherpetic Neuralgia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 372 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate efficacy and safety of pregabalin in the treatment of postherpetic neuralgia in a dose-ranging manner.

Conditions

• Neuralgia, Postherpetic

Interventions

Type	Name	Description
DRUG	Placebo	placebo, oral administration for 13 weeks (1 week titration and 12-week fixed dose).
DRUG	Pregabalin	Pregabalin 150mg/day (75mg BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
DRUG	Pregabalin	Pregabalin 300mg/day (150mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
DRUG	Pregabalin	Pregabalin 600 mg/day (300 mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).

Timeline

• Start date: 2006-09-01
• Primary completion: 2007-11-01
• Completion: 2007-11-01
• First posted: 2006-11-02
• Last updated: 2021-02-09
• Results posted: 2009-02-27

Locations

39 sites across 1 country: Japan